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Abstract
Background: Major hydrophilic region in genomic HBV extending from aa99 to aa169, clustered with a highly
conformational epitope, is critical to the antigenicity of hepatitis B surface antigen (HBsAg) and may affect the
diagnosis of HBV in HBV screening test. So, this study aimed to characterize variants of S gene product of hepatitis
B virus (HBV) isolated from patients with overt or occult HBV infection in north-eastern Egypt.
Methods: The study included sera of two different groups of volunteer blood donors (VBDs), 82 with overt HBV
that were positive for HBsAg and anti-HBc and 343 donors negative for HBsAg eligible for donation. Of the latter
group, only 44 were positive for anti-HBc. All anti-HBc positive sera were subjected to HBV DNA detection and
partial sequence analysis targeting the HBV S gene.
Results: HBV DNA was detected in 22.7 % of HBsAg-/anti-HBc + (10/44 patients) and in 90 % of HBsAg + donors
(74/82 patients) with significant statistical difference (P = 0.0001). Phylogenetic analysis showed that HBV strains
retrieved from both groups were of genotype D. Amino acid escape mutation T125M was detected in only 2
samples of the occult infection group and in none of the overt group (P = 0.01). Different amino acid substitutions
were identified in overt infection group: S143L/T (16.2 %, 12/74) and P120T/S (2.7 %, 2/74). Q129R was significantly
more frequent in cases with occult HBV infection (40 %, 4/10) than overt group (6.8 %, 5/74) (P = 0.01).
Conclusions: HBV genotype D predominated both in patients with overt and occult HBV infection. Different
profiles of amino acid substitutions in the major hydrophilic region were seen in these two groups in Egypt.
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Background
Hepatitis B virus (HBV) chronically infected 240 million
people and leads to hepatitis, liver cirrhosis, and hepato-
cellular carcinoma. It is considered a major health prob-
lem in the world, especially in Asia, the Middle East,
and Africa [1].
Hepatitis B surface antigen (HBsAg) is an envelope
glycoprotein that serves as a primary target for diagnosis
and immunoprophylaxis of HBV infection. The domin-
ant epitopes of HBsAg, which are the targets of neutral-
izing antibody responses, reside in the “a” determinant
(aa 124–147) within the major hydrophilic region (MHR).
Amino acid substitutions in the MHR can cause reduced
binding of anti-HBs antibodies, resulting in immune es-
cape [2]. The major hydrophilic region, extending from
aa99 to aa169, clustered with a highly conformational epi-
tope, is critical to the antigenicity of HBsAg. Thus, amino
acid substitution in the MHR, either from variants in nat-
ural isolates or mutants selected under immunological
pressure, could cause incorrect diagnoses of HBV in the
HBsAg screening test [3].
In Egypt, blood donation depends mainly on unpaid
voluntary donors that could be either replacement or
regular donors. Although, replacement donors could be
either relatives or neighbors of blood recipients, the do-
nated blood is used to replenish the stores of the blood
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bank rather to be given to a particular recipient except
when rare blood groups are needed on emergency set-
tings. Furthermore, selection of blood donors depends
upon a screening system that excludes the subjects posi-
tive for HBsAg, anti-HCV, anti-HIV and anti-treponema
antibody. Despite the importance of anti-HBc screening
for safer blood transfusion [2, 3], this serological marker
is not included in Egyptian blood bank screening. Then,
such screening system in Egypt would miss occult HBV
infection (OBI) among blood donors [2, 3].
Occult HBV infection (OBI) is defined as the long-
term persistence of HBV DNA, despite undetectable
HBsAg by regular immunoassays [4, 5]. Evidence from
different geographical regions documents that OBI is
globally distributed and potentially a major source of
HBV transmission through blood transfusion and organ
transplantation [6, 7]. In the Middle East, an estimated
2–5 % of the general population is chronically infected.
Over the last two decades, , the endemicity of hepatitis
B infection has been changed from high to intermediate
and low endemicity the prevalence of hepatitis B is lower
(2-6 %) [8–10].
HBV vaccination was introduced in Egypt in 1992 as
part of an expanded program of immunization for the
newborn, in addition to its availability for populations at
high risk (Mansour et al., 1993) [11]. The incidence of
OBI in Egypt was assessed by Attia [1998] [12]. In north
eastern Egypt where the current study was conducted,
Youssef and colleagues reported OBI in 35 (16.3 %) of
214 hospitalized patients with elevated ALT levels, while
only 10 (4.7 %) were positive for HBsAg [13].
This study aimed to characterize HBs antigen MHR
variants in cases with overt and occult HBV infection in
volunteer blood donors (VBDs).
Results
General characteristics of the studied cohorts
The study included 126 volunteer blood donors, consist-
ing of 44 HBsAg-negative/anti-HBc-positive men and 82
HBsAg-positive subjects (74 men and 8 women) (median
viral load was 157.5660 × 103 IU/m). Both groups were
matched regarding age and ALT level (Table 1). Female
gender was significantly more frequent in donors with
overt HBV infection compared to HBV-resolved group
(P = 0.049). A significantly higher frequency of detectable
HBV DNA by nested PCR was observed in cases with
overt HBV infection (74/82, 90 %) than in cases with occult
HBV infection (10/44, 22.7 %) (P = 0.0001). Sequencing
and phylogenetic analysis revealed that HBV sequences
were of genotype D (data not shown).
Genetic variants of HBsAg in the MHR
In this study, MHR variants were found in 27/74
(37.8 %) of cases with overt HBV infection and 3 in 5/10
(50 %) of cases with occult HBV. Five types of variants
were observed in donors with overt HBV infection. The
most prevalent variant was S143L/T detected in 12
(16.2 %) of sequences, followed by T115S in 7 (9.5 %),
Q129R in 5 (5.8 %), P120T/S in 2 (2.7 %), and K141R in
one (1.4 %) (Fig. 1a) (Table 1). In 10 cases with occult
HBV infection, a different profile of amino acid substitu-
tions was observed. The most frequent one was Q129R
in 4 (40 %) of the retrieved sequences, followed by
T125M in 2 (20 %) and P127T in one (10 %) sample
(Fig. 1b) (Table 1). The well-known G145A/R variant
was not observed in either the overt infection or occult
infection group. T125M and Q129R amino acid substi-
tutions were significantly more frequent in cases with
occult HBV infection than in overt HBV infection (2
and 4 of 10 vs. 0 and 5 of 74, P = 0.01 for each) (Table 1).
The most prevalent variant was S143L/T detected in
16.2 % of sequences, followed by T115S in 9.5 %, Q129R
in 5.8 %, P120T/S in 2.7 %, and K141R in 1.4 % (Fig. 1a)
(Table 1).
Among overt HBV group (82 patients), 47 patients
(57.3 %) had mild viremia (36 wild type/11 mutant type),
17 patients (20.7 %) had moderate viremia (9 wild type/8
mutant type), 3 patients (3.7 %) had high viremia (2 wild
type/1 mutant type), and 12 patients (14.6 %) had very
high viremia (7 wild type/5 mutant type). The remaining
8 samples that were negative by real time PCR and posi-
tive HBsAg were assumed to contain HBV DNA below
the detection limit of the assay.
In cases with occult HBV infection, a different profile
of amino acid substitutions was observed. The most
frequent one was Q129R in 40 % (4/10) of the retrieved
sequences, followed by T125M in 20 % and P127T in
one sample (Fig. 1b) (Table 1). The well-known G145A/R
variant was not observed in either the overt infection or
occult infection group. T125M and Q129R amino acid
substitutions were significantly more frequent in cases
with occult HBV infection than in overt HBV infection
(P = 0.01 for each) (Table 1).
Criteria of blood donors with “HBsAg-/anti-HBc+”serological
profile
According to positivity for anti-HBs, blood donors
with serological profile [(HBsAg-/anti-HBc+)] were
sub-classified into two groups; 17 cases positive for
both anti-HBc and anti-HBs [(anti-HBc+/anti-HBs+)]
and 27 positive for only anti-HBc [anti-HBc+/anti-HBs–)].
HBV DNA was detected in 10 samples, 5 in each group
with a prevalence of 29.4 % in the [(anti-HBc+/anti-HBs+)]
group, and 18.5 % in the [(anti-HBc+/anti-HBs-)] group.
T125M was detected in one case in the anti-HBc+/anti-
HBs + group (sample ID, OCU 18) and in one case in
the anti-HBc+/anti-HBs– group (sample ID, OCU 158)
(Fig. 1b) (Table 2). However, Q129R was observed more
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frequently in anti-HBc+/anti-HBs + group (3/5, 60 %)
than in anti-HBc+/anti-HBs– group (1/5, 20 %), but
this difference did not reach statistical significance.
Descriptive analysis of cases with occult HBV infection
HBV DNA was detected in 10 of 44 HBsAg-negative/
anti-HBc-positive blood donors (22.7 %). The mean age
of cases with occult HBV infection was 32.9 + 6.1 years,
all men (Table 3). All had normal ALT values (range; 9–
22 U/L). Interestingly, 5 cases were serologically positive
for anti-HBs. However, only two samples had an anti-
HBs level >100 IU/L (1000 IU/L and 147 IU/L in sam-
ples ID OCU 18 and OCU 43, respectively), while low
levels of anti-HBs were detected in the remaining 3 sam-
ples (23.5, 12.4, 12.2 IU/L in OCU234, OCU340 and
OCU243, respectively) (Table 3). T125M and Q129R
substitutions were simultaneously present in only one
subject positive for anti-HBs (OCU 18) (Table 3, Fig. 1b).
The T125M HBsAg variant in the MHR was detected in
one sample negative for anti-HBs (OCU158), while
Q129R alone was detected in a further 3 samples. One
of the latter was negative for anti-HBs (OCU 309) and
the remaining two were positive (OCU340, 243) (Table 3,
Fig. 1b). With the exception of one case all samples
showed low HBV DNA level [(OCU 274), HBV DNA =
4.7 log (copy/ml)]. The viral load for the remained cases
with occult HBV infection varied between 2.2-2.8 log
copy/ml and 3 cases were below the detection limit of the
assay. .Interestingly, the sample with the highest viral load
in the occult HBV infection group exhibits no amino acid
substitution in the MHR genomic region (OCU274).
Discussion
In this study, Occult HBV infection was detected in
22.7 % of blood donors negative for HBsAg but positive
for anti-HBc, indicating that at least a quarter of cases
positive for the latter had detectable HBV DNA and thus
the likelihood of transmission of HBV through their
blood products [14]. Said et al. (2013) reported an inci-
dence of 17.2 % among a cohort similar to that of the
current study [3]. Different risk factors are reported to
be associated with OBI including age, male gender, anti-
HBs level <100 mIU/L and positivity for anti-HBc in
Egypt [3].
In Egypt, HBV screening in blood banks relies only on
the detection of HBsAg. Screening for HBV by the nucleic
acid amplification test (NAT) is effective in reducing the
transmission of HBV via blood and blood products. In de-
veloping countries like Egypt, the high cost of the NAT
may prevent its application as an essential strategy for
blood-borne virus screening. Anti-HBc has been found to
be an excellent indicator of the occult HBV infection and
the detection of the anti-HBc [14–16] has contributed sig-
nificantly in reducing the incidence of post transfusion
hepatitis B [17, 18]. In this regard, measurement of anti-
HBc would be more practical and may be considered as a
second safeguard policy for reducing the transmission of
HBV via blood products [2]. Despite the importance of
anti-HBc screening for safer blood, this serological marker
is not included in Egyptian blood bank screening. Then,
such screening system in Egypt would miss OBI among
blood donors [2–4].
The predominance of infection with HBV genotype D
among cases with overt and occult HBV infection in
Egypt, a previous finding supported by the present study,
has allowed the analysis of S gene variants of HBV strains
isolated from cases with occult and overt HBV infection
who were resident in north eastern Egypt [19, 20]. The
selection of samples from volunteer blood donors gives a
more representative spectrum of the immune-pathological








Age (Years) Mean ± SD 29.1 ± 7.1 32.9 ± 6.1 28.0 ± 7 NS
Gender (M) 118 (93.7) 44 (100 %) 74 (90 %) 0.049
ALT (IU/L) 18.8 ± 10.6 18.6 ± 13.9 19 ± 7.2 NS
HBV DNA S region (+) 84 (66.7 %) 10 (22.7 %) 74 (90 %) 0.0001
MHR Substitutions (%) 34/84 (40.5) 7/10 (50)a 27/74 (37.8) 0.5
T115S 7/84 (8.3) 0 7/74 (9.5) NS
P120T/S 2/84 (2.3) 0 2/74 (2.7) NS
T125M 2/84 (2.3) 2/10 (20) 0 0.01
P127T 1/84 (1.2) 1/10 (10) 0 NS
Q129R 9/84 (10.7) 4/10 (40) 5 (5.8) 0.01
K141R 1/84 (1.2) 0 1 (1.4) NS
S143L/T 12/84 (14.3) 0 12 (16.2) NS
aTwo MHR mutants were present simultaneously in 2 cases; OCU18 and OCU158
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pattern of HBV infection in the general population than
patients’ samples that would bias the results toward a spe-
cific immune variant of the disease [21]. Understanding
the prevalence and types of HBsAg variants is of high im-
portance, because this will affect policy decisions relating
to vaccine and diagnostic reagent design.
The proportion of samples positive for anti-HBc anti-
body among HBsAg-negative blood donors was 12.8 %.
This is higher than that previously reported anti-HBc
prevalence rates among HBsAg-negative blood donors in
the Mediterranean region (2.1 in Iran) [22] and the
5.6 % in Saudi Arabia [23].
Data regarding the amino acid changes of HBsAg in
Egypt, particularly in the general population, are scarce.
Variations in the alpha determinant region were ob-
served in 37.8 % of strains isolated from HBsAg-positive
blood donors and in 50 % of occult HBV. The incidence
of HBsAg variants among random chronic carriers with
HBV genotype D varied between 15 % in Morocco and
17.2 % in Iran [24]. However, Garmini et al. (2011) re-
ported that the substitution rate in the MHR was 0.4 %
in HBV genotype D strains isolated from HBsAg-positive
blood donors in Iran [21]. Different studies in China
(where genotypes C and B are prevalent) documented
that mutation rates within HBsAg-positive blood donors
ranged between 14.7 % in Shandong province to 50 % in
Nanjing. This large difference was explained by the
wider application of HBV vaccine in Nanjing [25].
Studying the underlying mechanisms of the occult
HBV infection in certain poulationmay require; (1) large
size studied population and (2) in vitro and in vivo ex-
perimental work to explore the virological characteristics
of the detected substitutions. Despite the small number
of cases with occult HBV obtained in the present study,
all (with exception of one) exhibit a low viral load even
in cases with MHR mutants. This finding may support
the hypothesis that OBI cases are secondary to overt
HBV infection and represent a residual low viremia level
suppressed by strong immune response together with
histological derangements occurring during acute or
chronic HBV infection [22, 23].
Differences were observed between the two cohorts
studied here in the type of predominant amino acid sub-
stitutions in the isolated MHR of HBsAg despite both
groups originating from volunteer blood donors.
Fig. 1 Alignment of amino acid sequences of the HBV partial
surface gene encompassing the “a” determinant region isolated
from cases with overt HBV infection a and from cases with occult
HBV infection b. The detected sequences were aligned with respect
to a consensus sequence of HBV genotype D retrieved from DDBJ/
GenBank database. Dots in alignment indicate identity with the
consensus sequence of genotype D. First and second loop positions
are underlined in the consensus sequence of the genotype
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Significant predominance of amino acid substitutions
T125M and Q129R was observed in HBsAg isolated
from occult hepatitis B cases. In the study by Candotti et
al. (2008), T125M was detected in 11.9 % of cases with
occult HBV genotype D, while none of the patients with
occult HBV genotype A harbored this mutant strain
[26]. The T125M substitution represents a non-
conservative amino acid change which may affect the
conformation of the HBsAg a determinant region and
thus the binding of HBsAg-specific antibody [27]. How-
ever, one in vitro study indicated that this substitution
failed to influence the binding of HBsAg to monoclonal or
polyclonal antibodies [28].
Recent in vitro studies found that Q129R significantly
impaired virion and/or S protein secretion in HuH7 cells
and in mice is associated with lower reactivity in HBsAg
assays [29]. While T125M and Q129R were the predom-
inant HBsAg variants in these occult HBV cases, P120T
and S143L were more frequent in HBsAg + blood do-
nors. Interestingly, these substitutions were previously
described in blood donors with occult HBV infection of
genotype D [30].
In the present study, 29.4 % of cases positive for both
anti-HBc and anti-HBs possessed detectable levels of
HBV-DNA. These results are in accordance with those
of Brojer et al. (2006) [31] and Katsoulidou et al. (2009)
[32] who found that nearly 50 % of OBI are asymptom-
atic, apparently healthy blood donors carriers of anti-
HBs [31, 32]. Similarly, Yotsuyanagi et al. (2001) found
that low levels of HBV DNA was detected in the sera
from 19 (38 %) of 50 HBsAg-/anti-HBc + donors. In 8
(16 %) of them, HBV did not exist as immune complexes.
thus in a potentially infective form [33]. Part of this may be
explained by the findings of Levicnik-Stezinar et al. (2008)
who concluded that low levels of anti-HBs <100 mIU/L
have limited neutralizing capacity [34].
Conclusion
The profiles of the predominant amino acid substitu-
tions different between cases with occult and overt HBV
infection were detected in the alpha determinant region
of the HBsAg (MHR) in blood samples from Egyptian
donors. Further large population size studies are needed
to explore the magnitude of occult HBV infection in
Egypt and to detect HBsAg variants affecting reactivity
in the HBsAg assays. The present study highlights the
need for revising the strategy used for screening HBV in
blood donors and blood products in Egypt. In the light
of point the high cost of HBV DNA testing for all col-
lected blood units, the present study recommends the
inclusion of anti-HBc in the routine screening of blood
donors in Egypt.
Table 3 Descriptive analysis of cases with occult HBV infection
Sample ID Age ALT (IU/L) Anti-HBs Anti-HBs level (mIU/L) MHR amino acid substitutions HBV DNA (core region) HBV DNA Log (copy/ml)
OCU234 38 22 (+) 23.5 - (+) 2.8
OCU340 32 16 (+) 12.4 Q129R (+) 2.7
OCU18 28 12 (+) 1000.0 T125M, Q129R (−) <2.0
OCU43 31 23 (+) 147.2 - (+) 2.3
OCU243 38 9 (+) 12.2 Q129R (+) 2.8
OCU309 45 17 (−) 0.1 Q129R (−) <2.0
OCU302 33 17 (−) 0.8 - (+) 2.5
OCU274 32 12 (−) 9.3 - (+) 4.5
OCU158 24 17 (−) 0.1 T125M (+) <2.0
OCU311 28 12 (−) 2.9 - (−) 2.2










Age (Mean ± SD ) 30 ± 7.1 32.3 ± 6.7 28.3 ± 7.2 0.055
ALT (U/L) 20.5 ± 15.9 20.9 ± 15.9 20.2 ± 16.2 NS
HBV DNA S region (+) 10 (22.7 %) 5 (29.4 %) 5(18.5 %) NS
MHR substitutions
T125M 2/10 (20 %) 1/5 1/5 NS
Q129R 4/10 (40 %) 3/5 1/5 NS
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Study design
Donors
The studied subjects in this work included two different
groups of blood donors; the first group included 82 indi-
viduals who were positive for HBsAg and rejected for
donation. The second group included 343 donors who
were accepted for donation; being negative HBsAg, anti-
HCV, anti-HIV and anti-treponema antibody. All blood
donors were randomly selected from blood bank. Serum
samples from the 343 HBsAg-negative donors were
tested for antibodies to hepatitis B core antigen (anti-
HBc). Forty four (12.8 %) of 343 HBsAg-negative blood
donors were positive for anti-HBc. The latter group was
further serologically tested for HBsAg antibody (anti-
HBs). Finally the study included two groups of sera: one
positive for anti-HBc and negative for HBsAg (n = 44),
and the second group of HBsAg-positive sera (n = 82).
Serological Markers of HBV Infection
HBsAg was determined by ELISA (Diasorin, Italy) and
further confirmed by chemiluminescence enzyme im-
munoassay (CLEIA) (Fujirebio, Tokyo,Japan) with a de-
tection limit of 0.05 IU/ml. Anti-HBc and anti-HBs were
tested by enzyme immunoassay (EIA) (AxSYM; Abbott
Japan, Tokyo, Japan). All serologic assays were carried
out according to the manufacturer's instructions.
DNA Extraction
The HBV/DNA was extracted from 200 μl of serum
samples positive for HBsAg using the QIAamp DNA
MiniKit (QIAGEN, Inc., Hilden, Germany), and re-
suspended in 100 μl of a storage buffer provided by the
kit manufacturer.
HBV DNA Quantification
HBV-DNA was quantified by real-time detection poly-
merase chain reaction (RTD-PCR) primers according to
the previously described protocol. The method was
applied with slight modification as described previously
[14, 15]. The detection limit was 100 copies/ml. The
extracted samples were tested for the presence of HBV
DNA by 7500 Real time PCR machine to determine the





The 25 μl reaction mixture volume contained 0.5 μl of
each primer (10 pico mol/ul) and the probe (SB2), 6 μl
water (PCR-grade), 5 μl of DNA template and 12.5 μl of
the Taq polymerase. Cycling conditions were 10 min at
95 °C, 95 °C for 15 sec, and 60 °C for 1 min for 45 cycles.
Fluorescence acquisition was taken once per cycle using
FAM as a reporter dye and TAMARA as a quencher
dye. The detection limit was 100 copies/ml.
HBV genome amplification and sequencing
The S gene of the HBV genome (681 bp) was amplified by
hemi nested PCR using specific primers. The method was
applied with slight modification as described previously
[14, 35]. For the first PCR (nucleotide positions 18–989):
 forward primer (IS1):5'-AAGCTCTGCTAGA
TCCCAGAGT-3'
 Reverse primer (HS4R): 5'- CATACTTTCCAA
TCAATAGG-3'
For the second PCR (nucleotide positions 414–989):
 Forward primer (SB1): 5'- TGCTGCTATGC
CTCATCTTC-3'
 Reverse primer (HS4R): 5'- CATACTTTCCAA
TCAATAGG-3'
Cycling conditions were 7 min at 96 °C, 96 °C for 45 sec,
and 55 °C for 45 sec and 72 °C for 45 sec for 45 cycles.
For undetectable PCR products by the previous
PCR protocol, we performed hemi-nested PCR with
AmpliTaq Gold® DNA Polymerase (Applied Biosystems,
Waltham, MA, US). The amplicons of the genomic HBV
enclosed the a determinant region of the S gene was ob-
tained by hemi-nested PCR with forward primer HBSF2 :
(5'-CTTCATCCTGCTGCTATGCCT-3' [nt 406–426])
and reverse primer HBSR2: (5'-AAAGCCCAGGATGAT
GGGAT-3' [nt 608–627]) for the first PCR and forward
primer HBSF2 : (5'-CTTCATCCTGCTGCTATGCCT-3'
[nt 406–426]) and reverse primer HBSR3. The PCR
reaction was undertaken for 60 cycles (96 °C for 15 sec.,
60 °C for 1 min.) followed by an extension reaction
at 72 °C for 7 min.
The enhancerII/core promoter and precore regions of
the HBV genome were amplified by PCR with a forward
primer (IS2-2: 5′-CAT GGAGAC CAC CGT GAA
CGC-3′ [nt 1607–1627]) and reverse primer (HBV1917R:
5′-CTC CAC AGA AGC TCC AAA TTCTTT A-3′ [nt
1942–1918]). PCR was initiated by the hot-star technique.
The PCR reaction was undertaken for 60 cycles (96 °C for
15 sec., 60 °C for 1 min.) followed by an extension reaction
at 72 °C for 7 min.
Sequencing and Molecular Evolutionary Analysis of HBV
Amplicons were sequenced directly using the ABI Prism
Big Dye ver. 3.1 kit in the ABI 3100 DNA automated se-
quencer (Applied Biosystems, Foster City, CA, USA). All
sequences were analyzed in both forward and reverse
directions with same primers used for HBV genomic
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amplification. HBV genotypes were determined by se-
quence and molecular evolutionary analysis. Reference
HBV sequences were retrieved from the DDBJ/EMBL/
GenBank database, aligned by CLUSTALX, and genetic
distances estimated with the 6-parameter method in the
Hepatitis Virus Database (http://s2as02.genes.nig.ac.jp/)
[16]. Based on obtained distances, phylogenetic trees were
constructed by the neighbor-joining (NJ) method with the
mid-point rooting option. To confirm the reliability of the
phylogenetic trees, bootstrap resampling tests were per-
formed 1000 times for analysis by the ODEN program of
the National Institute of Genetics. The deduced amino
acid sequences of the HBsAg a-determinant regions in the
donor HBV strains were compared to the HBV genotype
D reference strains as proposed previously [17]; and to the
amino acid sequences as present in the public domain da-
tabases, using the protein–protein Blast utility [18]. The
nucleotide sequences data described in this paper will
appear in the DDBJ/EMBL/GenBank sequences data-
base with accession numbers; AB981241-AB981313
and AB981171-AB981180.
Statistical analysis
Statistical analysis was performed with the Fisher’s exact
probability test and the independent t-test for the con-
tinuous variables using the SPSS software package (SPSS,
Chicago, IL, USA). P-values (two-tailed) less than 0.05
were considered to be statistically significant.
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